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Abstract- Spinal cord injured (SCI) patients have sexual disorders including erectile dysfunction (ED), 
impotence, priapism, ejaculatory dysfunction and infertility. Treatments for erectile dysfunction include four 
steps. Step 1 involves smoking cessation, weight loss, and increasing physical activity. Step 2 is 
phosphodiesterase type 5 inhibitors (PDE5I) such as Sildenafil (Viagra), intracavernous injections of 
Papaverine or prostaglandins, and vacuum constriction devices. Step 3 is a penile prosthesis, and Step 4 is 
sacral neuromodulation (SNM). Priapism can be resolved spontaneously if there is no ischemia found on 
blood gas measurement or by Phenylephrine. For anejaculatory dysfunction, massage, vibrator, electrical 
stimulation and direct surgical biopsy can be used to obtain sperm which can then be used for intra-uterine or 
in-vitro fertilization. Infertility treatment in male SCI patients involves a combination of the above treatments 
for erectile and anejaculatory dysfunctions. The basic approach to and management of sexual dysfunction in 
female SCI patients are similar as for men but do not require treatment for erectile or ejaculatory problems. 
© 2012 Tehran University of Medical Sciences. All rights reserved.  
Acta Medica Iranica, 2012; 50(5): 295-299.  
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Introduction 
 
Spinal trauma complicated by spinal cord injury (SCI) is 
a devastating event on a personal and family level, as 
well as a great financial burden to society because of its 
attendant morbidity, expense, and prolonged treatment 
requirements (1, 2). 
The prevalence of SCI has been evaluated in two 
papers reporting ranges from 110 to 1120 and 223 to 
755 per million people (3,4). In a population based 
study, the point prevalence of SCI in Tehran was 
440/million (95% CI: 120-1140) (5). In Tehran, the 
incidence was 98/million in males and 47/million in 
females (6). SCI complications were evaluated in 5995 
complete motor SCI (ASIA A and B) patients supported 
by the Welfare Organization in Iran (7). The prevalence 
of sexual dysfunction in males was 32.4% and in 
females was 13.9%. Prevalence of infertility was 12.1% 
and 7.0% in males and females, respectively.     
 
Materials and Methods 
 
A literature review was performed using the terms 
“spinal cord”, “injury”, “patient”, “treatment”, 
“management”, “sex”, “sexual”, and “erectile 
dysfunction” in PubMed from 1966 to 20th July 2011. 
The reference lists of the identified articles were also 
reviewed.  
 
Results 
 
There is less known about SCI-related sexual 
dysfunction in females than in males. However, these 
studies have shown that when vaginal stimulation is 
done in SCI females and a normal control group, orgasm 
will happen in 100% of normal controls but in less than 
50% of T12-L1 SCI patients. In females with S2-S5 
lesions, only 17% achieved orgasm (8). 
In female SCI patients, fertility is possible. However, 
pregnancy needs careful observation for autonomic 
dysreflexia. For delivery, Oxytocin induction is  
contra-indicated but epidural anesthesia is recommended 
to decrease the risk of autonomic dysreflexia.  
Careful observation for bed sores, urinary tract 
infections (UTI), leg edema, thrombophlebitis, transient 
ischemic attack (TIA) and anemia is important. 
Meanwhile, sequential breast examination is necessary. 
In patients with cervical lesions, lactation typically 
continues for 3 months and then stops because of lack of 
stimulation. 
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Most men with SCI are infertile. Erectile dysfunction 
(ED), ejaculatory dysfunction and semen abnormalities 
contribute to the problem. Although sperm count is 
normal in SCI men, sperm motility is low. There is 
abnormal sperm viability and morphology, too. 
Genitourinary infection and endocrine abnormalities can 
also be present (9-11). 
 
Erectile dysfunction (ED) 
ED is defined by the National Institutes of Health 
(NIH) as the inability to achieve or maintain an erection 
sufficient for satisfactory sexual performance. ED is the 
most common sexual problem in men (10). The 
incidence increases with age and affects up to one third 
of men throughout their lives. It causes a considerable 
negative impact on close relationships, quality of life, 
and confidence (12). 
 
ED pathophysiology 
ED may result from variety of psychological and/or 
organic causes including vascular, neurogenic, 
hormonal, anatomic and drug-induced conditions. A 
normal sexual erectile response results from the 
interaction between neurotransmitters and vascular 
smooth muscle initiated by parasympathetic and 
sympathetic neuronal triggers that combine physical 
stimulation of the penis with sexual perception and 
desire. Nitric oxide produced from endothelial cells after 
parasympathetic stimuli triggers a molecular cascade 
that results in smooth muscle relaxation and arterial 
influx of blood into the corpus cavernosum. Then, 
compression of venous return occurs, and an erection 
arises (13). 
 
History taking and physical examination  
In a patient with SCI, history and physical 
examination are adequate in making an accurate 
diagnosis of ED in most cases. Sexual history should 
focus on erection adequacy, altered libido, quality and 
timing of orgasm, volume and form of ejaculate, 
presence of sexually-induced genital pain or penile 
curve and partner sexual function. 
The physical examination should evaluate blood 
pressure and heart rate; body habitus, for central obesity; 
and cardiovascular, neurologic, and genitourinary 
systems, including penile, testicular, and digital rectal 
examinations. 
 
Laboratory tests 
Laboratory workup is not initially necessary in SCI 
patients. However, if the first line of treatment for ED is 
not successful, laboratory assessment is recommended to 
include a fasting blood glucose level and lipid panel, 
thyroid-stimulating hormone, and testosterone level 
(14). 
 
Conservative management 
First-line therapy for ED consists of lifestyle 
changes, modifying drug therapy that may cause ED, 
and pharmacotherapy with phosphodiesterase type 5 
inhibitors (PDE5I). Obesity, inactive lifestyle, and 
smoking greatly increase the risk of ED. Grade A 
treatment recommendations, based on high-quality 
patient-oriented studies, suggest that PDE5I are the most 
effective oral drugs for the treatment of ED in SCI 
patients (15,16). Retail sales of the three most popular 
PDE5Is Sildenafil (Viagra), Tadalafil (Cialis), and 
Vardenafil (Levitra) approached $1.48 billion in 2007 
(17). 
Compared with placebo, Sildenafil has been shown 
to improve erections (74% versus 21%) (18) and results 
in more frequent intercourse attempts (57% versus 21%) 
(19). 
Approximately one third of men with ED do not 
respond to therapy with PDE5 inhibitors. In addition, 
these agents are not effective for improving libido (20).  
The three PDE5I are considered to be somewhat 
similar in effectiveness, but there are differences in 
dosing, onset of action, and duration of therapeutic 
effect (21).  
The standard dose for Sildenafil is 50 to 100 mg 
daily. Recommended time between onset of dosing and 
intercourse is one hour. Drug action starts in 14 to 60 
minutes and drug duration extends for up to four hours. 
Tadalafil and Vardenafil dose is 10 to 20 mg daily. 
Although the duration of action in Vardenafil and 
Sildenafil are similar, the duration of action for Tadalfil 
is up to 36 hours. 
There are no conclusive data to suggest that one 
PDE5I is better than others. An open-label trial 
established that patients preferred Tadalafil and 
Vardenafil over Sildenafil (22). However, nearly all 
evidence supports equal efficacy between Sildenafil and 
Vardenafil (23).  
Headache is the most frequently reported side effect 
of PDE5Is, occurring in roughly 10% of patients. 
PDE5Is should not be taken simultaneously with nitrates 
because this may lead to a synergistic effect, resulting in 
a potentially severe, even lethal, decrease in blood 
pressure.  
The most frequent predictor of success for PDE5I is 
upper motor neuron (UMN) lesion. Most patients 
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tolerate these medications well, and in a meta-analysis, 
only 1% of patients discontinued their PDE5I. However, 
PDE5Is had no positive effect on ejaculation except in 
one study (24).  
 
Testosterone 
There is a limited indication for testosterone in SCI 
patients. Testosterone supplementation in men with 
hypogonadism improves ED and libido but requires 
interval monitoring of hemoglobin, serum transaminase, 
and prostate-specific antigen levels because of an 
increased risk of prostate adenocarcinoma (25,26).  
Intracavernosal pressure and PDE5 activity are 
androgen-dependent. The prevalence of hypogonadism 
in men with ED is estimated to be 5 to 10 percent (27).  
In men with hypogonadism, testosterone is superior 
to placebo in improving erections and sexual function. 
Response rates are higher in primary versus secondary 
testicular failure.  Testosterone is also associated with 
improved satisfaction with erectile function and sexual 
desire (28). 
 
Second line treatment 
Intracavernous and intraurethral injection of 
Papaverine, intraurethral prostaglandins (29), and 
vacuum constriction devices are alternative therapeutic 
options when PDE5Is fail. Much lower doses of 
intracavernous injection is prescribed in SCI patients 
than those who have vasculopathies (29). Intra-
cavernosal Papaverine is more effective, better tolerated, 
and preferred by men over the intraurethral form. There 
is a danger for prolonged erection (priapism), which is a 
medical emergency. Priapism is most frequently treated 
with aspiration of blood from the corpus cavernosum. If 
this treatment is inadequate, then intra-cavernosal 
injections of Phenylephrine should be performed with 
hemodynamic monitoring. There is similar efficacy for 
intracavernosal Papaverine and oral PDE5I Sildenafil 
(30). 
 
Vacuum constriction devices 
Some patients refuse vacuum constriction devices 
treatment due to negative cultural perceptions, minor 
complications such as ecchymoses or petechiae, and 
lack of motivation. However, vacuum constriction is a 
reasonable, safe, and noninvasive alternative, and 
possibly a better initial treatment for the management of 
impotence secondary to SCI. 
Vacuum constriction is a noninvasive second-line 
option and has minor side effects. It is contraindicated in 
men with sickle cell anemia or blood dyscrasias and in 
those taking anticoagulants. The worst complication of 
constriction devices in SCI patients with loss of penile 
sensation would be ischemic gangrene of penis. 
 
Third line: Surgically implanted penile prostheses  
When first and second line therapies have failed, 
surgical implantation of an inflatable penile prosthesis 
can be considered in consultation with an urologist 
(31,32). There is a 16.7% complication rate associated 
with penile prostheses, which include wound infections, 
penile pain due to excessive prosthesis length, and 
displeasure due to the partner's abnormal sensation (33). 
 
Fourth line: Sacral neuromodulation (SNM) 
The fourth line of treatment can be SNM, which can 
be performed in patients with complete SCI in detrusor 
atonic phase 2-3 months after SCI (34). This minimally 
invasive surgical operation can be performed under local 
anesthesia. It involves insertion of an electrode in each 
S3 root, using anal sphincter contraction following 
stimulation to determine correct placement. Sievert et 
al., performed the procedure in 10 patients and 6 
controls and showed the procedure prevented detrusor 
overactivity and urinary incontinence, ensured normal 
bladder capacity, reduced urinary tract infection rates, 
and improved bowel and erectile functionality without 
nerve damage (34).  
 
Cognitive behavioral therapy  
Cognitive behavioral therapy aimed at improving 
relationships may help to improve ED (35). Education 
about medical and psychosocial etiologies of ED in 
combination with physician assurance may help patients 
return to normal male sexual function. 
Screening for cardiovascular risk factors should be 
considered in men with ED because symptoms of ED 
present on average three years earlier than symptoms of 
coronary artery disease. Men with ED are at increased 
risk of vascular diseases (36). 
 
Management of anejaculation 
Semen retrieval is necessary in the management of 
anejaculatory patients hoping to conceive and can be 
performed by penile vibratory stimulation, 
electroejaculation, prostate massage, and surgical sperm 
retrieval, Intravaginal insemination, intrauterine 
insemination (pregnancy rate 28.6% per couple), and in 
vitro fertilization (pregnancy rate of 68.75% per couple) 
can all be used (37). Intracytoplasmic sperm injection 
can be required if there is a low total motile sperm 
count. 
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Priapism might be seen in SCI males. Corporal blood 
gas measurement is recommended to confirm non-
ischemic priapism. Intracorporeal phenylephrine is used 
for priapism treatment. Spontaneous resolution might 
happen within 5 hours (38). 
Detrusor-external sphincter dyssynergia (DSD) is 
seen in SCI patients. DSD is a debilitating problem and 
even life expectancy can be affected. This can be 
managed with urethral stents and botulinum toxin 
injection. First line treatment is the use of antimuscarinic 
medication and catheterization. External sphincterotomy 
is the surgical option in refractory cases. However, it can 
lead to ED (39). 
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